{"id":350409,"date":"2026-11-17T14:47:34","date_gmt":"2026-11-17T09:17:34","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=350409"},"modified":"2026-11-17T14:47:34","modified_gmt":"2026-11-17T09:17:34","slug":"pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/","title":{"rendered":"3 Pathology Labs Chain, Active Pharmaceutical Ingredients Maker and Cables and Wires Maker Stocks With a Strong Future Roadmap: Dr. Lal PathLabs, Divi&#8217;s Laboratories and Polycab India"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Dr. Lal PathLabs, Divi&#8217;s Laboratories and Polycab India: ROE of 15.3% to 24.1% and FY22 to FY26 revenue CAGR of 5.1% to 24.1%. Prices as of 16 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three <strong>pathology, drug ingredient and cable stocks<\/strong> to watch are <strong>Dr. Lal PathLabs<\/strong>, <strong>Divi&#8217;s Laboratories<\/strong> and <strong>Polycab India<\/strong>. Their <strong>return on equity<\/strong> ranges from <strong>15.3% to 24.1%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 5.1% to 24.1%. Polycab India leads on both return on equity at 24.1% and revenue growth at 24.1% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Pathology, drug ingredient and cable stocks let investors follow companies that serve a growing part of the Indian economy. Dr. Lal PathLabs, Divi&#8217;s Laboratories and Polycab India cover a pathology labs chain, an active pharmaceutical ingredients maker and a cables and wires maker.<\/p>\n<p>This list covers three pathology, drug ingredient and cable stocks with complete current figures: Dr. Lal PathLabs, Divi&#8217;s Laboratories and Polycab India. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#What_Are_Pathology_Drug_Ingredient_and_Cable_Stocks\" title=\"What Are Pathology, Drug Ingredient and Cable Stocks?\">What Are Pathology, Drug Ingredient and Cable Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#Pathology_Drug_Ingredient_and_Cable_Stocks_at_a_Glance\" title=\"Pathology, Drug Ingredient and Cable Stocks at a Glance\">Pathology, Drug Ingredient and Cable Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#Why_Do_Pathology_Drug_Ingredient_and_Cable_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Pathology, Drug Ingredient and Cable Stocks Have a Strong Roadmap in India?\">Why Do Pathology, Drug Ingredient and Cable Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#Why_Dr_Lal_PathLabs_Features_Among_These_Pathology_Drug_Ingredient_and_Cable_Stocks\" title=\"Why Dr. Lal PathLabs Features Among These Pathology, Drug Ingredient and Cable Stocks\">Why Dr. Lal PathLabs Features Among These Pathology, Drug Ingredient and Cable Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#Why_Divis_Laboratories_Features_Among_These_Pathology_Drug_Ingredient_and_Cable_Stocks\" title=\"Why Divi&#8217;s Laboratories Features Among These Pathology, Drug Ingredient and Cable Stocks\">Why Divi&#8217;s Laboratories Features Among These Pathology, Drug Ingredient and Cable Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#Why_Polycab_India_Features_Among_These_Pathology_Drug_Ingredient_and_Cable_Stocks\" title=\"Why Polycab India Features Among These Pathology, Drug Ingredient and Cable Stocks\">Why Polycab India Features Among These Pathology, Drug Ingredient and Cable Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#Dr_Lal_PathLabs_vs_Divis_Laboratories_vs_Polycab_India_on_Key_Financials\" title=\"Dr. Lal PathLabs vs Divi&#8217;s Laboratories vs Polycab India on Key Financials\">Dr. Lal PathLabs vs Divi&#8217;s Laboratories vs Polycab India on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#Key_Risks_to_Check_Before_Investing_in_Pathology_Drug_Ingredient_and_Cable_Stocks\" title=\"Key Risks to Check Before Investing in Pathology, Drug Ingredient and Cable Stocks\">Key Risks to Check Before Investing in Pathology, Drug Ingredient and Cable Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#Final_Thoughts_on_Pathology_Drug_Ingredient_and_Cable_Stocks\" title=\"Final Thoughts on Pathology, Drug Ingredient and Cable Stocks\">Final Thoughts on Pathology, Drug Ingredient and Cable Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#What_are_pathology_drug_ingredient_and_cable_stocks\" title=\"What are pathology, drug ingredient and cable stocks?\">What are pathology, drug ingredient and cable stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#Which_pathology_drug_ingredient_and_cable_stocks_are_covered_in_this_list\" title=\"Which pathology, drug ingredient and cable stocks are covered in this list?\">Which pathology, drug ingredient and cable stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#Why_do_pathology_drug_ingredient_and_cable_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do pathology, drug ingredient and cable stocks have a strong future roadmap in India?\">Why do pathology, drug ingredient and cable stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#How_has_Dr_Lal_PathLabs_performed_financially\" title=\"How has Dr. Lal PathLabs performed financially?\">How has Dr. Lal PathLabs performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#How_has_Divis_Laboratories_performed_financially\" title=\"How has Divi&#8217;s Laboratories performed financially?\">How has Divi&#8217;s Laboratories performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#How_has_Polycab_India_performed_financially\" title=\"How has Polycab India performed financially?\">How has Polycab India performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#What_risks_should_investors_check_before_buying_pathology_drug_ingredient_and_cable_stocks\" title=\"What risks should investors check before buying pathology, drug ingredient and cable stocks?\">What risks should investors check before buying pathology, drug ingredient and cable stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and-wires-maker-stocks-roadmap-downland-list\/#Is_this_list_of_pathology_drug_ingredient_and_cable_stocks_investment_advice\" title=\"Is this list of pathology, drug ingredient and cable stocks investment advice?\">Is this list of pathology, drug ingredient and cable stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Pathology_Drug_Ingredient_and_Cable_Stocks\"><\/span><strong>What Are Pathology, Drug Ingredient and Cable Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Pathology, drug ingredient and cable stocks<\/strong> are listed companies that run pathology labs and collection centres, make active pharmaceutical ingredients and custom molecules for global drug makers, and make cables, wires and electrical goods. Their earnings depend on test volumes, ingredient demand and electrical demand.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Pathology_Drug_Ingredient_and_Cable_Stocks_at_a_Glance\"><\/span><strong>Pathology, Drug Ingredient and Cable Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/lalpathlab\/dr-lal-pathlabs-ltd-share-price-today\">Dr. Lal PathLabs<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,000.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">30,949<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">56.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.08<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/divislab\/divi's-laboratories-ltd-share-price-today\">Divi&#8217;s Laboratories<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11,080<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">241,311<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">82.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.00<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/polycab\/polycab-india-ltd-share-price-today\">Polycab India<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,955.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">115,291<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">42.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.02<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Dr. Lal PathLabs and Polycab India trade at a <strong>P\/E<\/strong> below the industry P\/E, while Divi&#8217;s Laboratories trades above it, which reflects the growth the market already expects. Readers comparing pathology, drug ingredient and cable stocks should look at <strong>return on equity<\/strong> and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Pathology_Drug_Ingredient_and_Cable_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Pathology, Drug Ingredient and Cable Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Pathology, drug ingredient and cable stocks have a strong roadmap in India because wider use of preventive tests, rising outsourcing of drug ingredients and heavy spending on power and housing keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Pathology.<\/strong> Families test more for preventive care.<\/li>\n<li><strong>Drug ingredients.<\/strong> Drug makers need reliable supply.<\/li>\n<li><strong>Cables and wires.<\/strong> Homes and factories need more wiring.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Dr_Lal_PathLabs_Features_Among_These_Pathology_Drug_Ingredient_and_Cable_Stocks\"><\/span><strong>Why Dr. Lal PathLabs Features Among These Pathology, Drug Ingredient and Cable Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the <strong>pathology, drug ingredient and cable stocks<\/strong> on this list, Dr. Lal PathLabs is one of India&#8217;s best-known diagnostics companies, operating a national reference laboratory with a hub-and-spoke network of labs, patient service centres and collection points.<\/p>\n<p>Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%.<\/p>\n<p>In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a <strong>market capitalisation<\/strong> of Rs 30,949 crore. The stock trades at a <strong>P\/E<\/strong> of 56.6, below the industry P\/E of 59.6.<\/p>\n<p><strong>Roadmap:<\/strong> Its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.<\/p>\n<p><strong>What to watch:<\/strong> Follow test volumes per patient and the balance between routine and specialised tests.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Divis_Laboratories_Features_Among_These_Pathology_Drug_Ingredient_and_Cable_Stocks\"><\/span><strong>Why Divi&#8217;s Laboratories Features Among These Pathology, Drug Ingredient and Cable Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the lab chain, active ingredient and wire shares on this list, Divi&#8217;s Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.<\/p>\n<p>In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%.<\/p>\n<p>Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P\/E of 82.5, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.<\/p>\n<p><strong>What to watch:<\/strong> Check the order flow in custom synthesis and the commissioning of new capacity.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Polycab_India_Features_Among_These_Pathology_Drug_Ingredient_and_Cable_Stocks\"><\/span><strong>Why Polycab India Features Among These Pathology, Drug Ingredient and Cable Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Polycab India is a leading maker of wires and cables, with a growing range of fast moving electrical goods that includes fans, lighting, switches and switchgear, and a project business in engineering and procurement.<\/p>\n<p>The company has a return on equity of 24.1%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 115,291 crore. The stock trades at a P\/E of 36.0, below the industry P\/E of 42.9.<\/p>\n<p>Revenue rose from Rs 12,294 crore in FY22 to Rs 29,120 crore in FY26, a compound annual growth rate of 24.1%. Net profit grew from Rs 845 crore in FY22 to Rs 2,708 crore in FY26, which works out to a compound annual growth rate of 33.8%.<\/p>\n<p><strong>Roadmap:<\/strong> Spending on housing, power networks and industry is lifting demand for cables, while the company is deepening its presence in consumer electricals through its dealer network. Capacity additions help it serve both retail and project customers.<\/p>\n<p><strong>What to watch:<\/strong> Monitor cable volumes and the growth of its consumer electricals range.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Lal_PathLabs_vs_Divis_Laboratories_vs_Polycab_India_on_Key_Financials\"><\/span><strong>Dr. Lal PathLabs vs Divi&#8217;s Laboratories vs Polycab India on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three pathology, drug ingredient and cable stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Dr. Lal PathLabs<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,140<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,864<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">510<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Divi&#8217;s Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,074<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11,067<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,568<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.2%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Polycab India<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12,294<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">29,120<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,708<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.3%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Polycab India posts the highest return on equity in this group at 24.1%. Polycab India combines the largest FY26 revenue at Rs 29,120 crore with the fastest revenue growth, a 24.1% compound annual rate. A useful habit with pathology, drug ingredient and cable stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Pathology_Drug_Ingredient_and_Cable_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Pathology, Drug Ingredient and Cable Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these <strong>pathology, drug ingredient and cable stocks<\/strong>, the main points are: Long-term lab chain, active ingredient and wire shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Capacity ramp up.<\/strong> New hospitals take time to fill beds and reach full returns.<\/li>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Raw material costs.<\/strong> Ingredient and packaging prices can move margins.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter pathology, drug ingredient and cable stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Pathology_Drug_Ingredient_and_Cable_Stocks\"><\/span><strong>Final Thoughts on Pathology, Drug Ingredient and Cable Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Pathology, drug ingredient and cable stocks reward investors who follow demand trends, order books and margins together. Dr. Lal PathLabs, Divi&#8217;s Laboratories and Polycab India each have a clear plan to grow. Based on the 16 November 2026 close, Dr. Lal PathLabs trades at Rs 2,000.7, Divi&#8217;s Laboratories at Rs 11,080 and Polycab India at Rs 7,955.5. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these <strong>pathology, drug ingredient and cable stocks<\/strong> to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track pathology, drug ingredient and cable stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_pathology_drug_ingredient_and_cable_stocks\"><\/span><strong>What are pathology, drug ingredient and cable stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Pathology, drug ingredient and cable stocks are listed companies that run pathology labs and collection centres, make active pharmaceutical ingredients and custom molecules for global drug makers, and make cables, wires and electrical goods. Their earnings depend on test volumes, ingredient demand and electrical demand. This list looks at three of them, Dr. Lal PathLabs, Divi&#8217;s Laboratories and Polycab India, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_pathology_drug_ingredient_and_cable_stocks_are_covered_in_this_list\"><\/span><strong>Which pathology, drug ingredient and cable stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Dr. Lal PathLabs, Divi&#8217;s Laboratories and Polycab India. Based on the 16 November 2026 close, Dr. Lal PathLabs traded at Rs 2,000.7, Divi&#8217;s Laboratories at Rs 11,080 and Polycab India at Rs 7,955.5. Their return on equity ranges from <strong>15.3% to 24.1%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 5.1% to 24.1%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_pathology_drug_ingredient_and_cable_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do pathology, drug ingredient and cable stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Pathology, drug ingredient and cable stocks have a strong roadmap in India because wider use of preventive tests, rising outsourcing of drug ingredients and heavy spending on power and housing keep widening the market for these companies. The main drivers are as follows. Pathology. Families test more for preventive care. Drug ingredients. Drug makers need reliable supply. Cables and wires. Homes and factories need more wiring. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Dr_Lal_PathLabs_performed_financially\"><\/span><strong>How has Dr. Lal PathLabs performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P\/E of 56.6, below the industry P\/E of 59.6. Looking ahead, its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Divis_Laboratories_performed_financially\"><\/span><strong>How has Divi&#8217;s Laboratories performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P\/E of 82.5, above the industry P\/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Polycab_India_performed_financially\"><\/span><strong>How has Polycab India performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 12,294 crore in FY22 to Rs 29,120 crore in FY26, a compound annual growth rate of 24.1%. Net profit grew from Rs 845 crore in FY22 to Rs 2,708 crore in FY26, which works out to a compound annual growth rate of 33.8%. The company has a return on equity of 24.1%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 115,291 crore. The stock trades at a P\/E of 36.0, below the industry P\/E of 42.9. Looking ahead, spending on housing, power networks and industry is lifting demand for cables, while the company is deepening its presence in consumer electricals through its dealer network. Capacity additions help it serve both retail and project customers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_pathology_drug_ingredient_and_cable_stocks\"><\/span><strong>What risks should investors check before buying pathology, drug ingredient and cable stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying <strong>pathology, drug ingredient and cable stocks<\/strong>. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material costs. Ingredient and packaging prices can move margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_pathology_drug_ingredient_and_cable_stocks_investment_advice\"><\/span><strong>Is this list of pathology, drug ingredient and cable stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are pathology, drug ingredient and cable stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Pathology, drug ingredient and cable stocks are listed companies that run pathology labs and collection centres, make active pharmaceutical ingredients and custom molecules for global drug makers, and make cables, wires and electrical goods. Their earnings depend on test volumes, ingredient demand and electrical demand. This list looks at three of them, Dr. Lal PathLabs, Divi's Laboratories and Polycab India, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which pathology, drug ingredient and cable stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Dr. Lal PathLabs, Divi's Laboratories and Polycab India. Based on the 16 November 2026 close, Dr. Lal PathLabs traded at Rs 2,000.7, Divi's Laboratories at Rs 11,080 and Polycab India at Rs 7,955.5. Their return on equity ranges from 15.3% to 24.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 24.1%.\"}},{\"@type\":\"Question\",\"name\":\"Why do pathology, drug ingredient and cable stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Pathology, drug ingredient and cable stocks have a strong roadmap in India because wider use of preventive tests, rising outsourcing of drug ingredients and heavy spending on power and housing keep widening the market for these companies. The main drivers are as follows. Pathology. Families test more for preventive care. Drug ingredients. Drug makers need reliable supply. Cables and wires. Homes and factories need more wiring. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Dr. Lal PathLabs performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P\/E of 56.6, below the industry P\/E of 59.6. Looking ahead, its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.\"}},{\"@type\":\"Question\",\"name\":\"How has Divi's Laboratories performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P\/E of 82.5, above the industry P\/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.\"}},{\"@type\":\"Question\",\"name\":\"How has Polycab India performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 12,294 crore in FY22 to Rs 29,120 crore in FY26, a compound annual growth rate of 24.1%. Net profit grew from Rs 845 crore in FY22 to Rs 2,708 crore in FY26, which works out to a compound annual growth rate of 33.8%. The company has a return on equity of 24.1%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 115,291 crore. The stock trades at a P\/E of 36.0, below the industry P\/E of 42.9. Looking ahead, spending on housing, power networks and industry is lifting demand for cables, while the company is deepening its presence in consumer electricals through its dealer network. Capacity additions help it serve both retail and project customers.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying pathology, drug ingredient and cable stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying pathology, drug ingredient and cable stocks. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material costs. Ingredient and packaging prices can move margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of pathology, drug ingredient and cable stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pathology, Drug Ingredient and Cable Stocks with a strong future roadmap: Dr. Lal PathLabs, Divi&#8217;s Laboratories and Polycab India. Compare price, valuation, return on equity and revenue growth as of 16 November 2026.<\/p>\n","protected":false},"author":38,"featured_media":350408,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[24997,24998,3803,6920,457,7536,24995,24996,19802,877],"class_list":["post-350409","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-active-ingredient-and-wire-shares","tag-api-makers-and-power-cables-stocks","tag-best-stocks","tag-diagnostics","tag-divis-laboratories","tag-dr-lal-pathlabs","tag-drug-ingredient-and-cable-stocks","tag-lab-chain","tag-pathology","tag-polycab-india"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["350408"],"rank_math_title":["Pathology, Drug Ingredient and Cable Stocks"],"rank_math_description":["Compare 3 pathology, drug ingredient and cable stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 16 Nov 2026."],"rank_math_focus_keyword":["pathology, drug ingredient and cable stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-pathology-labs-chain-active-pharmaceutical-ingredients-maker-and-cables-and.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=350409"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350409\/revisions"}],"predecessor-version":[{"id":350410,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350409\/revisions\/350410"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/350408"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=350409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=350409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=350409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}